Abstract Search

ea0070aep866 | Thyroid | ECE2020

Radioactive Iodine-Refractory (RAI) Differentiated Thyroid Cancer (rDTC): Analysis of the Canadian Patient Support Program (PSP) for the Prescription and Treatment Patterns of Lenvatinib (LEN)

Boucher Andree , Hortensia Mircescu , Geneviève Rondeau , Rebecca Leboeuf , Bernard Lemieux , Maryse Brassard , Marie-Hélène Massicotte , monika Krzyzanowska , Dean Ruether , Nathaniel Bouganim , Nathan Lamond , Shereen Ezzat , Eric Winquist , Scott Laurie , Neil Chua , Paul Klimo , Howard Lim , Ralph Wong , Ramji Zahra , Alexander Flint , Hauck Wendy , Sebastien Hotte

Differentiated thyroid carcinoma (DTC) is viewed as an indolent disease but 5–15% of patients (pts) become refractory to RAI treatment. This is associated with poor prognosis, a 3–6 years life expectancy and accounts for approximately 200 deaths per year in Canada. There is no universal definition of rDCT and management evolves over time, with either monitoring or systemic therapy including LEN. In the Select Study on LEN in DTC, LEN provided a 19.4 month (mo) medi...

0 shares

Endocrine Abstracts

Radioactive Iodine-Refractory (RAI) Differentiated Thyroid Cancer (rDTC): Analysis of the Canadian Patient Support Program (PSP) for the Prescription and Treatment Patterns of Lenvatinib (LEN)

BiosciAbstracts